Soligenix ThermoVax platform fit for Bundibugyo Ebola outbreak vaccine
Soligenix surges 134% premarket on ThermoVax platform fit for Bundibugyo Ebola outbreak vaccine
- May 26 PR highlights existing compatibility of ThermoVax with Bundibugyo virus antigen for rapid thermostable subunit vaccine development
- Prior bivalent/trivalent filovirus vaccines (Ebola/Sudan/Marburg) showed up to 100% protection in non-human primates and 2-year stability at 40°C+
- Ongoing DRC/Uganda Bundibugyo outbreak (246+ suspected cases, 80 deaths as of mid-May; declared PHEIC by WHO) creates timely relevance
- Platform enables ambient shipping, single-vial reconstitution; addresses lack of approved Bundibugyo vaccine
- Low-float microcap biotech reacts sharply to outbreak-linked news; aligns with retail/forum interest in Ebola plays
- Builds on company's existing Orphan Drug designations for related filoviruses and government funding history
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.